Olivia has developed expertise across a range of therapeutics areas over the course of 7+ years of experience in life sciences research and consulting, but she has a specific interest in rare diseases, immunology, and ophthalmology. In particular, she has a passion for supporting clients with highly innovative technology platforms in the development and commercialization of their therapies for patients with significant unmet need. During her time at ClearView, Olivia has assisted a wide array of clients, ranging from leading biopharmaceutical companies to early-stage biotechs, in addressing their highest-priority strategic issues. Through this diversity of experience, Olivia has a demonstrated track record of ensuring commercial, clinical, and scientific factors are effectively considered to address her clients’ strategic questions.
While her historical experience spans a broad range of project types, Olivia focuses on commercialization strategy, including new product planning, portfolio prioritization, M&A and due diligence support, and strategic launch planning. Olivia received her B.A. in Economics and a Secondary Field in Chemistry from Harvard University.
Bill Shew
David Gilman
David McClain
Debbi Amanti Belanger
Debbie Zhuang
Ketan Kapadia
Kevin Richard
Kim Goh
Klaus Bredl
Mike Rizzo
Philip Kenner
Richard Mynahan
Rishi Dalsania
Ryan Tubman
Sam Ulin
Seth Berman
Stephen Chang
Steven Chao
Stuart MacGregor
Jim Caruso
Sidnee Pinho
Kristine Hyde
Charles Mathews
Dave Konciak
Dean Griffiths
Jonathan Betts
Jonathan Hodgson
Mike Roy
Slater Hurst
Alec Marchuk
Alexander Lehrman
Allana Sanborn
Andrew Kang
Austin Hubbert
Beko Binder
Cem Salfati
Jessica Berard
Joanna Lee
Jonny Juliano
Kai-Ming Pu
Kelsey Yardumian
Maneesh Gujrati
Matthew Murphy
Matthew Pfister
Mike Murray
Olivia Piccione
Owen Im
Patrick Kuettner
Peter Goldman
Sarah Stapleton
Soyeon Park
Vini De Nadai
Steve Rubman
Lainey Miller